FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3208917612> ?p ?o ?g. }

• W3208917612 endingPage "S3" @default.
• W3208917612 startingPage "S3" @default.
• W3208917612 abstract "Purpose/Objective(s)To report the PROs of a phase III randomized trial evaluating TAS combined with dose-escalated RT for patients with intermediate risk prostate cancer.Materials/MethodsEligible patients had intermediate risk prostate cancer defined as harboring ≥ 1 of these risk factors: clinical stage T2b-T2c, Gleason score 7, or PSA > 10 to ≤ 20 ng/mL. Patients were randomized to dose-escalated RT alone (Arm 1) or RT plus TAS (Arm 2) consisting of LHRH agonist/antagonist with oral antiandrogen for 6 months. Validated PROs included the Expanded Prostate Cancer Index Composite (EPIC-50) and Patient-Reported Outcome Measurement Information System (PROMIS) Fatigue short form. PRO change scores, calculated for each patient as the follow-up score minus baseline score (at end of RT, 6, 12, and 60 months from start of RT) were compared between treatment arms using a two-sample t test. An effect size (ES) of 0.50 SD (standard deviation) of the baseline measure was considered clinically meaningful. For the PRO sample size, 200 patients per arm would provide 90% statistical power to detect an ES < 0.50 if the completion rate was only 60%. Mixed effect regression models were also utilized. Clinical outcomes are reported in a separate abstract.ResultsOf the 402 initial planned subset of trial patients who completed baseline PROs, PRO compliance was approximately 96%, 89%, 86% and 87% at end of RT, 6, 12 and 60 months, respectively. There were no significant differences between these 402 patients and the remaining patients on this trial with respect to age, race, performance status, # risk factors, or comorbidity score. While EPIC urinary and bowel scores decreased significantly by the end of RT in both arms, no clinically meaningful differences between arms were detected over time. For the EPIC hormonal and sexual domains, however, there were clinically meaningful differences between the two arms with greater (P < 0.0001) deficits in the RT + TAS arm. These differences improved over time, with ∼50% resolution by one year after treatment and no clinically meaningful differences by 5 years between arms. PROMIS-fatigue scores increased from baseline in both arms and were significantly higher in arm 2 at the end of RT (P = 0.016), though slightly lower at 12 and 60 months.ConclusionThe addition of TAS to dose-escalated RT demonstrated significant clinically meaningful declines in the EPIC hormonal and sexual domains, and increases in the PROMIS-fatigue scores, compared to RT alone. These scores gradually improved over time, with no clinically meaningful differences between arms in fatigue by one year, or in hormonal and sexual domains by 5 years. Beyond the clinical outcomes, these PRO results directly from patients provide added value to help patients make informed decisions among treatment options. To report the PROs of a phase III randomized trial evaluating TAS combined with dose-escalated RT for patients with intermediate risk prostate cancer. Eligible patients had intermediate risk prostate cancer defined as harboring ≥ 1 of these risk factors: clinical stage T2b-T2c, Gleason score 7, or PSA > 10 to ≤ 20 ng/mL. Patients were randomized to dose-escalated RT alone (Arm 1) or RT plus TAS (Arm 2) consisting of LHRH agonist/antagonist with oral antiandrogen for 6 months. Validated PROs included the Expanded Prostate Cancer Index Composite (EPIC-50) and Patient-Reported Outcome Measurement Information System (PROMIS) Fatigue short form. PRO change scores, calculated for each patient as the follow-up score minus baseline score (at end of RT, 6, 12, and 60 months from start of RT) were compared between treatment arms using a two-sample t test. An effect size (ES) of 0.50 SD (standard deviation) of the baseline measure was considered clinically meaningful. For the PRO sample size, 200 patients per arm would provide 90% statistical power to detect an ES < 0.50 if the completion rate was only 60%. Mixed effect regression models were also utilized. Clinical outcomes are reported in a separate abstract. Of the 402 initial planned subset of trial patients who completed baseline PROs, PRO compliance was approximately 96%, 89%, 86% and 87% at end of RT, 6, 12 and 60 months, respectively. There were no significant differences between these 402 patients and the remaining patients on this trial with respect to age, race, performance status, # risk factors, or comorbidity score. While EPIC urinary and bowel scores decreased significantly by the end of RT in both arms, no clinically meaningful differences between arms were detected over time. For the EPIC hormonal and sexual domains, however, there were clinically meaningful differences between the two arms with greater (P < 0.0001) deficits in the RT + TAS arm. These differences improved over time, with ∼50% resolution by one year after treatment and no clinically meaningful differences by 5 years between arms. PROMIS-fatigue scores increased from baseline in both arms and were significantly higher in arm 2 at the end of RT (P = 0.016), though slightly lower at 12 and 60 months. The addition of TAS to dose-escalated RT demonstrated significant clinically meaningful declines in the EPIC hormonal and sexual domains, and increases in the PROMIS-fatigue scores, compared to RT alone. These scores gradually improved over time, with no clinically meaningful differences between arms in fatigue by one year, or in hormonal and sexual domains by 5 years. Beyond the clinical outcomes, these PRO results directly from patients provide added value to help patients make informed decisions among treatment options." @default.
• W3208917612 created "2021-11-08" @default.
• W3208917612 creator A5000044683 @default.
• W3208917612 creator A5004625690 @default.
• W3208917612 creator A5004874300 @default.
• W3208917612 creator A5010337409 @default.
• W3208917612 creator A5013622492 @default.
• W3208917612 creator A5029766244 @default.
• W3208917612 creator A5036116989 @default.
• W3208917612 creator A5038171309 @default.
• W3208917612 creator A5038819739 @default.
• W3208917612 creator A5045162411 @default.
• W3208917612 creator A5049587168 @default.
• W3208917612 creator A5051762270 @default.
• W3208917612 creator A5052233371 @default.
• W3208917612 creator A5059255743 @default.
• W3208917612 creator A5072574772 @default.
• W3208917612 creator A5072807582 @default.
• W3208917612 creator A5076213753 @default.
• W3208917612 creator A5076831856 @default.
• W3208917612 creator A5079218939 @default.
• W3208917612 creator A5090754156 @default.
• W3208917612 date "2021-11-01" @default.
• W3208917612 modified "2023-10-02" @default.
• W3208917612 title "Dose Escalated Radiotherapy (RT) Alone or in Combination With Short-Term Total Androgen Suppression (TAS) for Intermediate Risk Prostate Cancer: Patient Reported Outcomes (PROs) From the NRG Oncology/RTOG 0815 Randomized Trial" @default.
• W3208917612 doi "https://doi.org/10.1016/j.ijrobp.2021.07.042" @default.
• W3208917612 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34700528" @default.
• W3208917612 hasPublicationYear "2021" @default.
• W3208917612 type Work @default.
• W3208917612 sameAs 3208917612 @default.
• W3208917612 citedByCount "1" @default.
• W3208917612 countsByYear W32089176122023 @default.
• W3208917612 crossrefType "journal-article" @default.
• W3208917612 hasAuthorship W3208917612A5000044683 @default.
• W3208917612 hasAuthorship W3208917612A5004625690 @default.
• W3208917612 hasAuthorship W3208917612A5004874300 @default.
• W3208917612 hasAuthorship W3208917612A5010337409 @default.
• W3208917612 hasAuthorship W3208917612A5013622492 @default.
• W3208917612 hasAuthorship W3208917612A5029766244 @default.
• W3208917612 hasAuthorship W3208917612A5036116989 @default.
• W3208917612 hasAuthorship W3208917612A5038171309 @default.
• W3208917612 hasAuthorship W3208917612A5038819739 @default.
• W3208917612 hasAuthorship W3208917612A5045162411 @default.
• W3208917612 hasAuthorship W3208917612A5049587168 @default.
• W3208917612 hasAuthorship W3208917612A5051762270 @default.
• W3208917612 hasAuthorship W3208917612A5052233371 @default.
• W3208917612 hasAuthorship W3208917612A5059255743 @default.
• W3208917612 hasAuthorship W3208917612A5072574772 @default.
• W3208917612 hasAuthorship W3208917612A5072807582 @default.
• W3208917612 hasAuthorship W3208917612A5076213753 @default.
• W3208917612 hasAuthorship W3208917612A5076831856 @default.
• W3208917612 hasAuthorship W3208917612A5079218939 @default.
• W3208917612 hasAuthorship W3208917612A5090754156 @default.
• W3208917612 hasBestOaLocation W32089176121 @default.
• W3208917612 hasConcept C105795698 @default.
• W3208917612 hasConcept C121608353 @default.
• W3208917612 hasConcept C126322002 @default.
• W3208917612 hasConcept C126894567 @default.
• W3208917612 hasConcept C129848803 @default.
• W3208917612 hasConcept C143998085 @default.
• W3208917612 hasConcept C146357865 @default.
• W3208917612 hasConcept C151730666 @default.
• W3208917612 hasConcept C168563851 @default.
• W3208917612 hasConcept C2776235491 @default.
• W3208917612 hasConcept C2778559712 @default.
• W3208917612 hasConcept C2780192828 @default.
• W3208917612 hasConcept C33923547 @default.
• W3208917612 hasConcept C509974204 @default.
• W3208917612 hasConcept C535046627 @default.
• W3208917612 hasConcept C71924100 @default.
• W3208917612 hasConcept C86803240 @default.
• W3208917612 hasConceptScore W3208917612C105795698 @default.
• W3208917612 hasConceptScore W3208917612C121608353 @default.
• W3208917612 hasConceptScore W3208917612C126322002 @default.
• W3208917612 hasConceptScore W3208917612C126894567 @default.
• W3208917612 hasConceptScore W3208917612C129848803 @default.
• W3208917612 hasConceptScore W3208917612C143998085 @default.
• W3208917612 hasConceptScore W3208917612C146357865 @default.
• W3208917612 hasConceptScore W3208917612C151730666 @default.
• W3208917612 hasConceptScore W3208917612C168563851 @default.
• W3208917612 hasConceptScore W3208917612C2776235491 @default.
• W3208917612 hasConceptScore W3208917612C2778559712 @default.
• W3208917612 hasConceptScore W3208917612C2780192828 @default.
• W3208917612 hasConceptScore W3208917612C33923547 @default.
• W3208917612 hasConceptScore W3208917612C509974204 @default.
• W3208917612 hasConceptScore W3208917612C535046627 @default.
• W3208917612 hasConceptScore W3208917612C71924100 @default.
• W3208917612 hasConceptScore W3208917612C86803240 @default.
• W3208917612 hasIssue "3" @default.
• W3208917612 hasLocation W32089176121 @default.
• W3208917612 hasLocation W32089176122 @default.
• W3208917612 hasOpenAccess W3208917612 @default.
• W3208917612 hasPrimaryLocation W32089176121 @default.
• W3208917612 hasRelatedWork W1980188241 @default.
• W3208917612 hasRelatedWork W1980245127 @default.
• W3208917612 hasRelatedWork W1982816235 @default.
• W3208917612 hasRelatedWork W2106003470 @default.
• W3208917612 hasRelatedWork W2127440557 @default.

• next